Header Logo

Connection

Philip Comp to Fibrinolytic Agents

This is a "connection" page, showing publications Philip Comp has written about Fibrinolytic Agents.
Connection Strength

0.412
  1. Selective factor Xa inhibition improves efficacy of venous thromboembolism prophylaxis in orthopedic surgery. Pharmacotherapy. 2003 Jun; 23(6):772-87.
    View in: PubMed
    Score: 0.207
  2. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group. J Bone Joint Surg Am. 2001 Mar; 83(3):336-45.
    View in: PubMed
    Score: 0.177
  3. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2005 May; 3(5):962-8.
    View in: PubMed
    Score: 0.015
  4. The activation and effects of protein C, an antithrombotic protein, in vivo. Surv Synth Pathol Res. 1984; 3(1):31-7.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.